Lonza Group AG (0QNO) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thanks to all our guests for joining the call today. Good afternoon to those of you based in Europe and good morning to those of you joining from the US. This time last year, I joined the half-year results call to briefly introduce myself to you, but I was still very much the new joiner, having commenced my tenure as CEO just a couple of days before. This call today marks a milestone as I have now completed my first year in the role. And it has been a pleasure to meet many of you at our investor update and on our roadshows since then. And I'm looking forward to continuing our dialogue during our scheduled trips in the coming months. Today also marks a milestone for OneLonsa as we report on the performance of our newly formed business platforms for the first time. You will recall that we used to report on four divisions, even up until the Q1 qualitative update. However, we have now formally transitioned to our three new CDMO business platforms, integrated biologics, advanced synthesis, and specialized modalities. Alongside these three core CDMO platforms, we will also be reporting on capsules and health ingredients, CHI, of course, which continues to operate in its existing structure. We will also share an update on our exit plans for that part of our business. But before we jump into the details of our half-year results, let's have a quick look at our disclaimer regarding forward-looking statements that Philip and myself will be making during this call. This is also available in the online version of our presentation for you to download and read in your precious spare time. Looking at our agenda today, we will start with our group business and some of the highlights and key events over the course of H1. I will then hand over to Philip, who will do a deep dive into ke...